Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.

Niemi RJ, Braicu EI, Kulbe H, Koistinen KM, Sehouli J, Puistola U, Mäenpää JU, Hilvo M.

Br J Cancer. 2018 Oct 8. doi: 10.1038/s41416-018-0270-z. [Epub ahead of print]

PMID:
30293997
2.

Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths.

Ruuth M, Nguyen SD, Vihervaara T, Hilvo M, Laajala TD, Kondadi PK, Gisterå A, Lähteenmäki H, Kittilä T, Huusko J, Uusitupa M, Schwab U, Savolainen MJ, Sinisalo J, Lokki ML, Nieminen MS, Jula A, Perola M, Ylä-Herttula S, Rudel L, Öörni A, Baumann M, Baruch A, Laaksonen R, Ketelhuth DFJ, Aittokallio T, Jauhiainen M, Käkelä R, Borén J, Williams KJ, Kovanen PT, Öörni K.

Eur Heart J. 2018 Jul 14;39(27):2562-2573. doi: 10.1093/eurheartj/ehy319.

3.

Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients.

Anroedh S, Hilvo M, Akkerhuis KM, Kauhanen D, Koistinen K, Oemrawsingh R, Serruys P, van Geuns RJ, Boersma E, Laaksonen R, Kardys I.

J Lipid Res. 2018 Sep;59(9):1729-1737. doi: 10.1194/jlr.P081281. Epub 2018 Jun 1.

PMID:
29858423
4.

Ceramide stearic to palmitic acid ratio predicts incident diabetes.

Hilvo M, Salonurmi T, Havulinna AS, Kauhanen D, Pedersen ER, Tell GS, Meyer K, Teeriniemi AM, Laatikainen T, Jousilahti P, Savolainen MJ, Nygård O, Salomaa V, Laaksonen R.

Diabetologia. 2018 Jun;61(6):1424-1434. doi: 10.1007/s00125-018-4590-6. Epub 2018 Mar 15.

PMID:
29546476
5.

PCSK9 inhibition alters the lipidome of plasma and lipoprotein fractions.

Hilvo M, Simolin H, Metso J, Ruuth M, Öörni K, Jauhiainen M, Laaksonen R, Baruch A.

Atherosclerosis. 2018 Feb;269:159-165. doi: 10.1016/j.atherosclerosis.2018.01.004. Epub 2018 Jan 12.

PMID:
29366988
6.

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism.

Braicu EI, Darb-Esfahani S, Schmitt WD, Koistinen KM, Heiskanen L, Pöhö P, Budczies J, Kuhberg M, Dietel M, Frezza C, Denkert C, Sehouli J, Hilvo M.

Oncotarget. 2017 Oct 26;8(61):102912-102922. doi: 10.18632/oncotarget.22076. eCollection 2017 Nov 28.

7.

Identification and characterization of a novel zebrafish (Danio rerio) pentraxin-carbonic anhydrase.

Patrikainen MS, Tolvanen MEE, Aspatwar A, Barker HR, Ortutay C, Jänis J, Laitaoja M, Hytönen VP, Azizi L, Manandhar P, Jáger E, Vullo D, Kukkurainen S, Hilvo M, Supuran CT, Parkkila S.

PeerJ. 2017 Dec 7;5:e4128. doi: 10.7717/peerj.4128. eCollection 2017.

8.

Lipidomic profiling of patient-specific iPSC-derived hepatocyte-like cells.

Kiamehr M, Viiri LE, Vihervaara T, Koistinen KM, Hilvo M, Ekroos K, Käkelä R, Aalto-Setälä K.

Dis Model Mech. 2017 Sep 1;10(9):1141-1153. doi: 10.1242/dmm.030841. Epub 2017 Jul 21.

9.

Liver-specific deletion of the Plpp3 gene alters plasma lipid composition and worsens atherosclerosis in apoE-/- mice.

Busnelli M, Manzini S, Hilvo M, Parolini C, Ganzetti GS, Dellera F, Ekroos K, Jänis M, Escalante-Alcalde D, Sirtori CR, Laaksonen R, Chiesa G.

Sci Rep. 2017 Mar 14;7:44503. doi: 10.1038/srep44503.

10.

Circulating Ceramides Predict Cardiovascular Outcomes in the Population-Based FINRISK 2002 Cohort.

Havulinna AS, Sysi-Aho M, Hilvo M, Kauhanen D, Hurme R, Ekroos K, Salomaa V, Laaksonen R.

Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2424-2430. Epub 2016 Oct 20.

PMID:
27765765
11.

Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol.

Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, Suoniemi M, Hurme R, März W, Scharnagl H, Stojakovic T, Vlachopoulou E, Lokki ML, Nieminen MS, Klingenberg R, Matter CM, Hornemann T, Jüni P, Rodondi N, Räber L, Windecker S, Gencer B, Pedersen ER, Tell GS, Nygård O, Mach F, Sinisalo J, Lüscher TF.

Eur Heart J. 2016 Jul 1;37(25):1967-76. doi: 10.1093/eurheartj/ehw148. Epub 2016 Apr 28.

12.

Prolonged sleep restriction induces changes in pathways involved in cholesterol metabolism and inflammatory responses.

Aho V, Ollila HM, Kronholm E, Bondia-Pons I, Soininen P, Kangas AJ, Hilvo M, Seppälä I, Kettunen J, Oikonen M, Raitoharju E, Hyötyläinen T, Kähönen M, Viikari JS, Härmä M, Sallinen M, Olkkonen VM, Alenius H, Jauhiainen M, Paunio T, Lehtimäki T, Salomaa V, Orešič M, Raitakari OT, Ala-Korpela M, Porkka-Heiskanen T.

Sci Rep. 2016 Apr 22;6:24828. doi: 10.1038/srep24828.

13.

Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas.

Hilvo M, de Santiago I, Gopalacharyulu P, Schmitt WD, Budczies J, Kuhberg M, Dietel M, Aittokallio T, Markowetz F, Denkert C, Sehouli J, Frezza C, Darb-Esfahani S, Braicu EI.

Cancer Res. 2016 Feb 15;76(4):796-804. doi: 10.1158/0008-5472.CAN-15-2298. Epub 2015 Dec 18.

14.

The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy.

Jørgenrud B, Jalanko M, Heliö T, Jääskeläinen P, Laine M, Hilvo M, Nieminen MS, Laakso M, Hyötyläinen T, Orešič M, Kuusisto J.

PLoS One. 2015 Aug 12;10(8):e0134184. doi: 10.1371/journal.pone.0134184. eCollection 2015.

15.

Fish oil and krill oil differentially modify the liver and brain lipidome when fed to mice.

Skorve J, Hilvo M, Vihervaara T, Burri L, Bohov P, Tillander V, Bjørndal B, Suoniemi M, Laaksonen R, Ekroos K, Berge RK, Alexson SE.

Lipids Health Dis. 2015 Aug 11;14:88. doi: 10.1186/s12944-015-0086-2.

16.

The metabolic alterations of cancer cells.

Sciacovelli M, Gaude E, Hilvo M, Frezza C.

Methods Enzymol. 2014;542:1-23. doi: 10.1016/B978-0-12-416618-9.00001-7. Review.

PMID:
24862258
17.

Steroid and steroid glucuronide profiles in urine during pregnancy determined by liquid chromatography-electrospray ionization-tandem mass spectrometry.

Jäntti SE, Hartonen M, Hilvo M, Nygren H, Hyötyläinen T, Ketola RA, Kostiainen R.

Anal Chim Acta. 2013 Nov 13;802:56-66. doi: 10.1016/j.aca.2013.09.034. Epub 2013 Sep 30.

PMID:
24176505
18.

Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients.

Hilvo M, Gade S, Hyötyläinen T, Nekljudova V, Seppänen-Laakso T, Sysi-Aho M, Untch M, Huober J, von Minckwitz G, Denkert C, Orešič M, Loibl S.

Int J Cancer. 2014 Apr 1;134(7):1725-33. doi: 10.1002/ijc.28491. Epub 2013 Oct 8.

19.

Characterization, bioinformatic analysis and dithiocarbamate inhibition studies of two new α-carbonic anhydrases, CAH1 and CAH2, from the fruit fly Drosophila melanogaster.

Syrjänen L, Tolvanen ME, Hilvo M, Vullo D, Carta F, Supuran CT, Parkkila S.

Bioorg Med Chem. 2013 Mar 15;21(6):1516-21. doi: 10.1016/j.bmc.2012.08.046. Epub 2012 Aug 31.

PMID:
22989910
20.

Metabolic associations of reduced proliferation and oxidative stress in advanced breast cancer.

Jerby L, Wolf L, Denkert C, Stein GY, Hilvo M, Oresic M, Geiger T, Ruppin E.

Cancer Res. 2012 Nov 15;72(22):5712-20. doi: 10.1158/0008-5472.CAN-12-2215. Epub 2012 Sep 17.

21.

Remodeling of central metabolism in invasive breast cancer compared to normal breast tissue - a GC-TOFMS based metabolomics study.

Budczies J, Denkert C, Müller BM, Brockmöller SF, Klauschen F, Györffy B, Dietel M, Richter-Ehrenstein C, Marten U, Salek RM, Griffin JL, Hilvo M, Orešič M, Wohlgemuth G, Fiehn O.

BMC Genomics. 2012 Jul 23;13:334. doi: 10.1186/1471-2164-13-334.

22.

Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery.

Denkert C, Bucher E, Hilvo M, Salek R, Orešič M, Griffin J, Brockmöller S, Klauschen F, Loibl S, Barupal DK, Budczies J, Iljin K, Nekljudova V, Fiehn O.

Genome Med. 2012 Apr 30;4(4):37.

23.

Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress.

Ketola K, Hilvo M, Hyötyläinen T, Vuoristo A, Ruskeepää AL, Orešič M, Kallioniemi O, Iljin K.

Br J Cancer. 2012 Jan 3;106(1):99-106. doi: 10.1038/bjc.2011.530.

24.

Phospholipase PLA2G7, associated with aggressive prostate cancer, promotes prostate cancer cell migration and invasion and is inhibited by statins.

Vainio P, Lehtinen L, Mirtti T, Hilvo M, Seppänen-Laakso T, Virtanen J, Sankila A, Nordling S, Lundin J, Rannikko A, Orešič M, Kallioniemi O, Iljin K.

Oncotarget. 2011 Dec;2(12):1176-90.

25.

15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells.

Lehtinen L, Vainio P, Wikman H, Reemts J, Hilvo M, Issa R, Pollari S, Brandt B, Oresic M, Pantel K, Kallioniemi O, Iljin K.

J Pathol. 2012 Mar;226(4):674-86. doi: 10.1002/path.3956. Epub 2012 Jan 17.

PMID:
22072156
26.

Integration of metabolomics and expression of glycerol-3-phosphate acyltransferase (GPAM) in breast cancer-link to patient survival, hormone receptor status, and metabolic profiling.

Brockmöller SF, Bucher E, Müller BM, Budczies J, Hilvo M, Griffin JL, Orešič M, Kallioniemi O, Iljin K, Loibl S, Darb-Esfahani S, Sinn BV, Klauschen F, Prinzler J, Bangemann N, Ismaeel F, Fiehn O, Dietel M, Denkert C.

J Proteome Res. 2012 Feb 3;11(2):850-60. doi: 10.1021/pr200685r. Epub 2011 Dec 15.

PMID:
22070544
27.

Brain phenotype of carbonic anhydrase IX-deficient mice.

Pan PW, Parkkila AK, Autio S, Hilvo M, Sormunen R, Pastorekova S, Pastorek J, Haapasalo H, Parkkila S.

Transgenic Res. 2012 Feb;21(1):163-76. doi: 10.1007/s11248-011-9520-z. Epub 2011 May 6.

PMID:
21547424
28.

Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression.

Hilvo M, Denkert C, Lehtinen L, Müller B, Brockmöller S, Seppänen-Laakso T, Budczies J, Bucher E, Yetukuri L, Castillo S, Berg E, Nygren H, Sysi-Aho M, Griffin JL, Fiehn O, Loibl S, Richter-Ehrenstein C, Radke C, Hyötyläinen T, Kallioniemi O, Iljin K, Oresic M.

Cancer Res. 2011 May 1;71(9):3236-45. doi: 10.1158/0008-5472.CAN-10-3894. Epub 2011 Mar 17.

29.

Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325).

Dehing-Oberije C, Aerts H, Yu S, De Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B, Lambin P.

Int J Radiat Oncol Biol Phys. 2011 Oct 1;81(2):360-8. doi: 10.1016/j.ijrobp.2010.06.011. Epub 2010 Oct 1.

PMID:
20888135
30.

Characterization of the first beta-class carbonic anhydrase from an arthropod (Drosophila melanogaster) and phylogenetic analysis of beta-class carbonic anhydrases in invertebrates.

Syrjänen L, Tolvanen M, Hilvo M, Olatubosun A, Innocenti A, Scozzafava A, Leppiniemi J, Niederhauser B, Hytönen VP, Gorr TA, Parkkila S, Supuran CT.

BMC Biochem. 2010 Jul 26;11:28. doi: 10.1186/1471-2091-11-28.

31.

Global transcriptional response to carbonic anhydrase IX deficiency in the mouse stomach.

Kallio H, Hilvo M, Rodriguez A, Lappalainen EH, Lappalainen AM, Parkkila S.

BMC Genomics. 2010 Jun 23;11:397. doi: 10.1186/1471-2164-11-397.

32.

The most recently discovered carbonic anhydrase, CA XV, is expressed in the thick ascending limb of Henle and in the collecting ducts of mouse kidney.

Saari S, Hilvo M, Pan P, Gros G, Hanke N, Waheed A, Sly WS, Parkkila S.

PLoS One. 2010 Mar 10;5(3):e9624. doi: 10.1371/journal.pone.0009624.

33.

A survey of carbonic anhydrase mRNA expression in enamel cells.

Lacruz RS, Hilvo M, Kurtz I, Paine ML.

Biochem Biophys Res Commun. 2010 Mar 19;393(4):883-7. doi: 10.1016/j.bbrc.2010.02.116. Epub 2010 Feb 20.

34.

Inhibition and binding studies of carbonic anhydrase isozymes I, II and IX with benzimidazo[1,2-c][1,2,3]thiadiazole-7-sulphonamides.

Baranauskienė L, Hilvo M, Matulienė J, Golovenko D, Manakova E, Dudutienė V, Michailovienė V, Torresan J, Jachno J, Parkkila S, Maresca A, Supuran CT, Gražulis S, Matulis D.

J Enzyme Inhib Med Chem. 2010 Dec;25(6):863-70. doi: 10.3109/14756360903571685. Epub 2010 Feb 18.

PMID:
20166809
35.

Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX.

Alterio V, Hilvo M, Di Fiore A, Supuran CT, Pan P, Parkkila S, Scaloni A, Pastorek J, Pastorekova S, Pedone C, Scozzafava A, Monti SM, De Simone G.

Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16233-8. doi: 10.1073/pnas.0908301106. Epub 2009 Sep 14.

36.

The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian alpha-carbonic anhydrase isoforms.

Parkkila S, Innocenti A, Kallio H, Hilvo M, Scozzafava A, Supuran CT.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4102-6. doi: 10.1016/j.bmcl.2009.06.002. Epub 2009 Jun 6.

PMID:
19527930
37.

Carbonic anhydrase activators. Activation of the membrane-associated isoform XV with amino acids and amines.

Innocenti A, Hilvo M, Parkkila S, Scozzafava A, Supuran CT.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3430-3. doi: 10.1016/j.bmcl.2009.05.026. Epub 2009 May 12.

PMID:
19464888
38.

Cloning, expression, post-translational modifications and inhibition studies on the latest mammalian carbonic anhydrase isoform, CA XV.

Hilvo M, Salzano AM, Innocenti A, Kulomaa MS, Scozzafava A, Scaloni A, Parkkila S, Supuran CT.

J Med Chem. 2009 Feb 12;52(3):646-54. doi: 10.1021/jm801267c.

PMID:
19193158
39.

Carbonic anhydrase inhibitors: the membrane-associated isoform XV is highly inhibited by inorganic anions.

Innocenti A, Hilvo M, Parkkila S, Scozzafava A, Supuran CT.

Bioorg Med Chem Lett. 2009 Feb 15;19(4):1155-8. doi: 10.1016/j.bmcl.2008.12.082. Epub 2008 Dec 25.

PMID:
19128966
40.

Carbonic anhydrase inhibitors: synthesis and inhibition studies against mammalian isoforms I-XV with a series of 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H-indole-5-sulfonamides.

Güzel O, Innocenti A, Scozzafava A, Salman A, Parkkila S, Hilvo M, Supuran CT.

Bioorg Med Chem. 2008 Oct 15;16(20):9113-20. doi: 10.1016/j.bmc.2008.09.032. Epub 2008 Sep 13.

PMID:
18819811
41.

Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes.

Hilvo M, Baranauskiene L, Salzano AM, Scaloni A, Matulis D, Innocenti A, Scozzafava A, Monti SM, Di Fiore A, De Simone G, Lindfors M, Jänis J, Valjakka J, Pastoreková S, Pastorek J, Kulomaa MS, Nordlund HR, Supuran CT, Parkkila S.

J Biol Chem. 2008 Oct 10;283(41):27799-809. doi: 10.1074/jbc.M800938200. Epub 2008 Aug 13.

42.

Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide.

Di Fiore A, Monti SM, Hilvo M, Parkkila S, Romano V, Scaloni A, Pedone C, Scozzafava A, Supuran CT, De Simone G.

Proteins. 2009 Jan;74(1):164-75. doi: 10.1002/prot.22144.

PMID:
18618712
43.

Carbonic anhydrase inhibitors: Inhibition of the new membrane-associated isoform XV with phenols.

Innocenti A, Hilvo M, Scozzafava A, Parkkila S, Supuran CT.

Bioorg Med Chem Lett. 2008 Jun 15;18(12):3593-6. doi: 10.1016/j.bmcl.2008.04.077. Epub 2008 May 4.

PMID:
18501600
44.

Recent advances in research on the most novel carbonic anhydrases, CA XIII and XV.

Hilvo M, Innocenti A, Monti SM, De Simone G, Supuran CT, Parkkila S.

Curr Pharm Des. 2008;14(7):672-8. Review.

PMID:
18336313
45.

Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomas.

Haapasalo J, Hilvo M, Nordfors K, Haapasalo H, Parkkila S, Hyrskyluoto A, Rantala I, Waheed A, Sly WS, Pastorekova S, Pastorek J, Parkkila AK.

Neuro Oncol. 2008 Apr;10(2):131-8. doi: 10.1215/15228517-2007-065. Epub 2008 Mar 5.

46.

Carbonic anhydrase inhibitors: the very weak inhibitors dithiothreitol, beta-mercaptoethanol, tris(carboxyethyl)phosphine and threitol interfere with the binding of sulfonamides to isozymes II and IX.

Innocenti A, Hilvo M, Scozzafava A, Lindfors M, Nordlund HR, Kulomaa MS, Parkkila S, Supuran CT.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):1898-903. doi: 10.1016/j.bmcl.2008.02.008. Epub 2008 Feb 9.

PMID:
18295485
47.

Effects of iron loading on muscle: genome-wide mRNA expression profiling in the mouse.

Rodriguez A, Hilvo M, Kytömäki L, Fleming RE, Britton RS, Bacon BR, Parkkila S.

BMC Genomics. 2007 Oct 19;8:379.

48.

Characterization and inhibition of the recently discovered carbonic anhydrase isoforms CA XIII, XIV and XV.

Hilvo M, Supuran CT, Parkkila S.

Curr Top Med Chem. 2007;7(9):893-9. Review.

PMID:
17504134
49.

Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis.

Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastoreková S, Pastorek J, Parkkila SM, Haapasalo HK.

Clin Cancer Res. 2006 Jan 15;12(2):473-7.

50.

Characterization of CA XV, a new GPI-anchored form of carbonic anhydrase.

Hilvo M, Tolvanen M, Clark A, Shen B, Shah GN, Waheed A, Halmi P, Hänninen M, Hämäläinen JM, Vihinen M, Sly WS, Parkkila S.

Biochem J. 2005 Nov 15;392(Pt 1):83-92.

Supplemental Content

Support Center